大麻药物基因组学：通往个性化医疗之路。
Cannabis Pharmacogenomics: A Path to Personalized Medicine.
作者信息
Babayeva Mariana, Loewy Zvi G
机构信息
Department of Biomedical and Pharmaceutical Sciences, Touro College of Pharmacy, New York, NY 10027, USA.
Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA.
出版信息
Curr Issues Mol Biol. 2023 Apr 17;45(4):3479-3514. doi: 10.3390/cimb45040228.
Cannabis and related compounds have created significant research interest as a promising therapy in many disorders. However, the individual therapeutic effects of cannabinoids and the incidence of side effects are still difficult to determine. Pharmacogenomics may provide the answers to many questions and concerns regarding the cannabis/cannabinoid treatment and help us to understand the variability in individual responses and associated risks. Pharmacogenomics research has made meaningful progress in identifying genetic variations that play a critical role in interpatient variability in response to cannabis. This review classifies the current knowledge of pharmacogenomics associated with medical marijuana and related compounds and can assist in improving the outcomes of cannabinoid therapy and to minimize the adverse effects of cannabis use. Specific examples of pharmacogenomics informing pharmacotherapy as a path to personalized medicine are discussed.
大麻及相关化合物作为一种在多种疾病中颇具前景的治疗方法，引发了大量的研究兴趣。然而，大麻素的个体治疗效果及副作用发生率仍难以确定。药物基因组学或许能为许多有关大麻/大麻素治疗的问题和担忧提供答案，并帮助我们理解个体反应的变异性及相关风险。药物基因组学研究在识别对大麻反应的患者间变异性中起关键作用的基因变异方面取得了有意义的进展。本综述对与医用大麻及相关化合物相关的药物基因组学的现有知识进行了分类，有助于改善大麻素治疗的效果，并将大麻使用的不良反应降至最低。文中讨论了药物基因组学为药物治疗提供信息以实现个性化医疗的具体实例。
Zotero 插件